FXR Agonist

LH10 is a fexaramine-based agonist for FXR with an EC₅₀ of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models.

Lecufexor is a farnesoid X receptor (FXR) agonist.

Tauro-obeticholic acid-d₅ sodium is deuterium labeled Tauro-obeticholic acid sodium (HY-135399A). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.

Arjungenin (Standard) is the analytical standard of Arjungenin. This product is intended for research and analytical applications. Arjungenin, a pentacyclic triterpenoid compound, is a FXR agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV).

FXR/HSD17B13-modulator-2 is a dual FXR activator and HSD17B13 inhibitor with human FXR EC₅₀ of 128 nM, human HSD17B13 IC₅₀ of 0.18 μM, high selectivity over related nuclear receptors and HSD17B isoforms, and oral effectiveness.FXR/HSD17B13-modulator-2 alleviates fatty liver, regulates lipid metabolism, reduces inflammation, and attenuates hepatic fibrosis.FXR/HSD17B13-modulator-2 is the first non-carboxylic acid dual FXR/HSD17B13 modulator.FXR/HSD17B13-modulator-2 can be used for the research of metabolic dysfunction-associated steatohepatitis.

ST-1892 (compound 14) is a highly potent FXR agonist (EC₅₀=7.2 nM) that can be used to study diseases or disorders caused by metabolic inflammation.

GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC₅₀ of 120 nM. GSK2324 exhibits t_1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively.

Tauro-obeticholic acid sodium is an active metabolite of Obeticholic acid (HY-12222). Obeticholic acid is a potent, selective and orally active FXR agonist.

LY2562175 (Standard) is the analytical standard of LY2562175 (HY-103704). This product is intended for research and analytical applications. LY2562175 is a potent and selective FXR agonist, with an EC₅₀ of 193 nM.

Tropifexor (Standard) is the analytical standard of Tropifexor (HY-107418). This product is intended for research and analytical applications. Tropifexor (LJN452) is a highly potent agonist of FXR with an EC₅₀ of 0.2 nM.

Cilofexor (Standard) is the analytical standard of Cilofexor (HY-109083). This product is intended for research and analytical applications. Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC₅₀ of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research.

Vonafexor (Standard) is the analytical standard of Vonafexor (HY-109197). This product is intended for research and analytical applications. Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research.

T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.

Altenusin shows markedly DPPH radical scavenging activities.

Tauro-obeticholic acid-d₅ is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.

Turofexorate isopropyl (Standard) is the analytical standard of Turofexorate isopropyl. This product is intended for research and analytical applications. Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM.

DM175 is a partial agonist of FXR. DM175 binds to the ligand-binding domain of FXR and induces the outward movement of Trp454.

Fexaramine (Standard) is the analytical standard of Fexaramine. This product is intended for research and analytical applications. Fexaramine is a potent and selective FXR agonist with an EC50 of 25 nM. Fexaramine has no activity against hRXRα, hPPARαγδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ, and hVDR receptors.

Nidufexor (Standard) is the analytical standard of Nidufexor (HY-109096). This product is intended for research and analytical applications. Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH).